EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF^V600E Mutated Parent- and Vemurafenib-Resistant Melanoma

• Main Authors: Yige Fu (Author), Drishti Rathod (Author), Ehab M. Abo-Ali (Author), Vikas V. Dukhande (Author), Ketan Patel (Author)
• Format: Book
• Published: MDPI AG, 2019-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The clinical outcomes of malignant melanoma have improved with the introduction of mitogen-activated protein kinase kinase (MEK) inhibitors. However, off-target toxicities of the MEK inhibitor trametinib (TMB) often result in dose interruption and discontinuation of therapy. The purpose of this stud...